Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma

European Journal of Haematology

Volumn 87, Issue 3, 2011, Pages 281-284

  Calvo Villas, José M ^a   Alegre, Adrián ^b   Calle, Carmen ^c   Hernández, Miguel T ^d   García Sánchez, Ricarda ^e   Ramírez, Gema ^e  

^a HOSPITAL GENERAL DE LANZAROTE   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KARYOTYPE; KIDNEY FAILURE; LETTER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL;

HUMANS; MULTIPLE MYELOMA; SALVAGE THERAPY; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84860389253     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01644.x     Document Type: Letter

References (13)

1. Rosiñol L, Cibeira MT, Bladé J, Esteve J, Aymerich M, Rozman M, Segarra M, Cid MC, Filella X, Montserrat E. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004;89:832-6.
2. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001;28:1145-50.
3. Bladé J, Perales M, Rosiñol L, et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001;13:422-5.
4. Avigdor A, Raanami P, Levi I, Hardan I, Ben-Bassat I. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leuk Lymphoma 2001;42:683-7.
5. Myers B, Grimley C, Crouch D, Dolan G. Lack of response to thalidomide in plasmacytomas. Br J Haematol 2001;115:234.
6. Rosiñol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Bladé J, Montserrat E. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405-8.
7. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005;90:278-9.
8. Paubelle E, Coppo P, Garderet L, Azizi L, Bories D, Gorin NC, Fouillard L. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect. Leukemia 2005;19:1702-4.
9. Krauth MT, Bankier A, Valent P, Kalhs P, Drach J. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leuk Res 2005;29:1473-7.
10. Katodritou E, Gastari V, Verrou E, et al. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res 2009;33:1137-40.
11. Sher T, Miller KC, Deeb G, Lee K, Chanan-Khan A. Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 2010;150:418-27.
12. Alegre A, Aguado B, Giraldo P, et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. Int J Hematol 2011;93:351-60.
13. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.